Clinical research site network CenExel Clinical Research announced on Tuesday the appointment of Dr. Sy Pretorius as chief executive officer, effective 1 May 2026.
Dr. Pretorius succeeds Ryan Brooks, who will remain a member of the company's board of directors.
CenExel said that Dr. Pretorius joins the company with more than three decades of experience in clinical research leadership, spanning senior executive and management roles where he was instrumental in driving global clinical development programmes, early-phase research, and integrated clinical trial services.
Dr. Pretorius currently serves as CEO of Ergomed Group, where he leads value creation efforts across the PrimeVigilance, Ergomed CRO and ADAMAS businesses after the group transitioned from the public market to private equity ownership. Prior to joining Ergomed, he served as chief operating officer at EVERSANA, where he led drug and device commercialisation services. Earlier, as president of Clinical Development and chief medical officer at PAREXEL, he oversaw a USD3.6bn global P&L and led more than 16,000 employees worldwide.
Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Laronix and Greater Baltimore Medical Center launch Laronix MIRA Voice investigational study
BD receives CE Mark for Revello vascular covered stent
GAIA and Daiichi Sankyo Europe partner on digital therapeutic for cardiovascular care
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
BD receives FDA clearance for Surgiphor 1000mL irrigation system
Galderma secures EU, US and Canada approval for new Restylane syringe
Philips launches InkSpace Imaging Snuggle coil for 3.0T MRI systems
Realheart secures European patent for artificial heart technology
Median Technologies secures FDA clearance for AI lung cancer screening software
Eli Lilly to invest over USD3.5bn in new Pennsylvania plant
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval